Viking Therapeutics Inc Stock
€60.74
Your prediction
Viking Therapeutics Inc Stock
Pros and Cons of Viking Therapeutics Inc in the next few years
Pros
Cons
Performance of Viking Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | 1.380% | 29.814% | 36.956% | 372.134% | 247.383% | 1172.308% | - |
| Evolus Inc | -2.650% | 1.852% | 12.821% | 60.584% | 21.547% | 24.294% | - |
| Ardelyx Inc. | 2.140% | 2.012% | -9.675% | 64.190% | -10.519% | 300.930% | - |
| Coherus Bioscien. | 1.100% | 5.090% | 1.315% | -61.381% | -48.043% | -85.770% | -89.721% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination of Viking's financial statements, the company's financial situation seems challenging, which is a common scenario in the biotechnology and medical research industry. Companies in this field often face significant losses and capital expenditures before reaching profitability. The next step is to provide a detailed analysis of the company's financials to understand the pros and cons better.
1. Strong Cash Position: Viking's cash position has improved over the years, despite a slight decline observed in the recent quarter. At the end of 2020, the company held $29,117,000 in cash, which grew to $36,632,000 at the end of 2022. This implies that the company has enough liquidity to support its ongoing operations and invest in future opportunities.
2. Substantial Investments: Cash flow statements reveal that between 2020 and 2022, Viking consistently invested in its business, totaling over $120 million in short-term investments. These investments can create long-term value for the company and are a positive sign for its shareholders.
Comments
News
Viking Therapeutics: Pharma Stock Soars on Positive Earnings
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics'
Why Viking Therapeutics Stock Is Skyrocketing Today
Shares of Viking Therapeutics (NASDAQ: VKTX) were skyrocketing 32.3% as of 11:21 a.m. ET on Thursday. The big gain came after the clinical-stage biopharmaceutical company provided its second-quarter
This 6%-Yielding Dividend Stock Is About to Get a Boost From the Biggest IPO of 2024
Lineage Logistics, a real estate investment trust (REIT) focused on cold storage facilities, is preparing to go public. It's seeking to raise up to $3.9 billion -- a $19.2 billion valuation --